

03/09/01
4042 U.S. PTO

33-12-01

Box Sug/ A

UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR 1.53(b))	Attorney Docket No. 1671.003 (35784/208786)
	First Inventor or Application Identifier: Whitehouse
	Title of Invention: METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION
	Express Mail Label No. EM166865433US

ADDRESS TO: **BOX PATENT APPLICATION
COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231**

Transmitted herewith for filing in the United States Patent Office is a patent application for:

Inventors: Martha Jo Whitehouse
151 Upper Terrace
San Francisco, CA 94117

JC996 U.S. PTO
09/802365
03/09/01

1. ☒ The Filing Fee has been calculated as shown below:

2. ☐ Applicant claims Small Entity Status. See 37 CFR 1.27.

	No. Filed	No. Extra	Small Entity	Large Entity
			Rate Fee 0	Rate Fee 1
BASIC FEE			\$0	\$710
TOTAL CLAIMS:	29 - 20 =	9	X 9 = \$0	x 18 = \$162
INDEP CLAIMS:	2 - 3 =	0	X 40 = \$0	x 80 = \$0
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED			+135 = \$	+270 = \$
*If the difference in Column 1 is less than zero, enter "0" in Column 2.			TOTAL \$	TOTAL \$872

a. ☒ Fees required under 37 CFR 1.16 (National filing fees).

b. ☒ Fees required under 37 CFR 1.17 (National application processing fees).

☒ A check in the amount of \$ 872.00 for the filing fee is enclosed.

☐ The above filing fee will be paid along with Applicant(s) Response to the Notice to File Missing Parts.

3. ☒ Specification; Total Pages 29

4. ☐ _____ Sheets of Formal Drawing(s) (35 USC 113)

5. ☐ Declaration and Power of Attorney; [Total Pages _____]

a. ☐ Newly executed (original or copy)

b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)

i. ☐ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) & 1.33(b).

6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☒ Computer Readable Copy (CRF)
 - b. ☐ Request for Transfer of Computer Readable Form of Sequence Listing under 37 CFR § 1.821(e) and MPEP 2422.05
 - c. ☒ Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ Paper (6 Pages)
 - d. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s) (including a check for the \$40.00 fee)
10. ☐ 37 CFR 3.73(b) Statement (*when there is an assignee*); ☐ Power of Attorney
11. ☐ English Translation Document (*if applicable*)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449; ___ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (*Should be specifically itemized*)
15. ☐ Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
Foreign Priority is
16. ☐ Request and Certification for Non-publication under 35 U.S.C. 122(b)(2)(B)(i).
Applicant **must** attach form PTO/SB35 or its equivalent.
17. ☐ Request for Early Publication Under 37 CFR § 1.219. Fee of \$300.00 is enclosed.
18. **If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CF 1.76:**
☐ Continuation ☐ Divisional ☐ Continuation in Part (CIP)
of prior Application No: ___; Filed ___
Prior Application Information: Examiner _____ Group/Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Chiron Corporation
Intellectual Property
P.O. Box 8097
Emeryville, CA 94662-8097
Tel. (510) 655-8730
Fax (510) 655-3542

Signature: _____

Agent of Record: Leslie T. Henry
Agent Registration No. 45,714

Alston & Bird LLP

Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000

Tel Raleigh Office (919) 420-2200
Fax Raleigh Office (919) 420-2260

"Express Mail" mailing label number EM166865433US

Date of Deposit March 9, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner For Patents, Washington, DC 20231.

Polly P. Burton

Polly P. Burton

RTA01/2092680v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Whitehouse
Appl. No.: Not yet assigned
Filed: March 9, 2001
For: METHODS AND COMPOSITIONS FOR THE TREATMENT
AND PREVENTION OF ERECTILE DYSFUNCTION




STATEMENT IN SUPPORT OF FILING A
SEQUENCE LISTING UNDER 37 CFR § 1.821(f)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted concurrently herewith in accordance with 37 CFR § 1.821(c) and (e), are the same.


Respectfully submitted,


Leslie T. Henry
Agent for Applicant
Registration No. 45,714

Alston & Bird LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 420-2200
Fax Raleigh Office (919) 420-2260

"Express Mail" Mailing Label Number EM166865433US
Date of Deposit: March 9, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner for Patents, Washington, DC 20231.


Polly P. Burton

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on March 9, 2001.